RecipientAmountDeal/Technology HighlightLead InvestorsDeal TypeCountry
Impax Laboratories, Inc$6,400 millionThe combined company will have a robust generics business that will rank as the 5th largest in the United States by gross revenue and a growing, high-margin specialty franchise.Amneal Pharmaceuticals LLCMergerUnited States
Advanced Accelerator Applications (AAA)$3,900 millionIntegration of AAA would build on Novartis' expertise in diseases associated with NETs and introduce a new technology platform to Novartis providing an innovative approach to treating cancer.Novartis Acquisition France
CureVac AG$1,800 millionDevelopment and commercialization of up to five potential cancer vaccine products based on CureVac's proprietary RNActive® technologyEli Lilly and Company Collaboration Germany
CytomX $1,500 millionDevelop a CytomX Probody™ T-cell engaging bispecific against the Epidermal Growth Factor Receptor (EGFR), a highly validated oncology target expressed on multiple human cancer types.Amgen Collaboration United States
MacroGenics, Inc.$900 millionDevelopment and commercialization of Anti-PD-1 Monoclonal Antibody MGA012 in all indications.Incyte CorporationExclusive Worldwide RightsUnited States
Kirin Holdings$780 millionAmgen will own the product rights and remaining cash held by Kirin-Amgen.Amgen (Amgen & Kirin Holdings (Kirin))AcquisitionJapan
KalVista Pharmaceuticals, Inc.$760 millionDevelopment of investigational plasma kallikrein inhibitors (KVD001) for treatment of diabetic macular edema DMEMerckCollaborationUnited States
Exactech $625 millionExactech is leading developer and producer of orthopaedic implant devices and surgical instrumentation for extremities and large jointsTPG CapitalMergerUnited States
HemoShear Therapeutics, LLC$470 millionTo discover and develop novel therapeutics for liver diseases, including nonalcoholic steatohepatitis (NASH).Takeda Pharmaceutical Company LimitedPartnership United States
Warp Drive Bio, Inc.$387 millionTo advance novel classes of antibiotics to combat multi-drug-resistant bacterial infections.RocheCollaboration United States
Apama Medical Inc$300 millionTo Strengthen Electrophysiology Portfolio and Expand into "Single-Shot" Balloon Pulmonary Vein Isolation Treatments for Patients with Atrial FibrillationBoston Scientific CorporationAcquisitionUnited States
Poxel SA$300 millionDevelopment and commercialization of Imeglimin, an investigational therapeutic agent for type 2 diabetes, in Japan, China and eleven other Asian countriesSumitomo Dainippon Pharma Marketing & Development RightsFrance
Bioprojet SCR$270 millionExclusive US right to develop, register and market the drug pitolisantHarmony Biosciences, LLCExclusive US RightFrance
Invendo Medical GmbH$265 millionInvendo medical is a leading developer of sterile, single-use HD endoscopy products in the field of gastroenterology and gastrointestinal surgery. Ambu A/S AcquisitionGermany
Alector$225 millionTo advance innovative new therapies for Alzheimer's disease.AbbVieCollaborationUnited States
JOTEC$225 millionThe combination of CryoLife and JOTEC will create a Company with a broad and highly competitive product portfolio focused on aortic surgeryCryoLifeAcquisitionGermany
NIH$215 million Partnership for Accelerating Cancer TherapiesAbbVie, Amgen,
Boehringer Ingelheim
Pharma GmbH & Co. KG,
Bristol-Myers
Squibb, Celgene Corporation,
Genentech, Gilead Sciences,
GlaxoSmithKline plc, 
Janssen Pharmaceutical Companies of 
Johnson & Johnson, 
Novartis, and Pfizer, Inc.
Partnership United States
Vexim$213 millionVEXIM, a French medical device company, specializes in the development and sale of vertebral compression fracture (VCF) solutions.Stryker AcquisitionFrance
Rotation Medical$210 millionRotation Medical Inc., is a developer of a novel tissue regeneration technology for shoulder rotator cuff repairSmith & NephewAcquisitionUnited States
ADC Therapeutics $200 millionTo progress ADCT-301 and ADCT-402 currently in four clinical studies in important sub-types of lymphoma and leukemia into planned registrational trials in 2018Auven Therapeutics, Redmile, 
the Wild Family Office & AstraZeneca.
FinancingSwitzerland
Karyopharm Therapeutics Inc.$193.0 millionTo develop and commercialize Selinexor and KPT-8602 in Japan and other countries in AsiaOno Pharmaceutical Co., LtdExclusive License AgreementUnited States
Ablynx$182.3 millionAblynx NV is a late-stage clinical biopharmaceutical company utilising its proprietary Nanobody® platform to develop treatments for a broad range of therapeutic indications with an unmet medical need.UndisclosedIPO FundingBelgium
Symbiomix Therapeutics$150 million Symbiomix Therapeutics is a biopharmaceutical company bringing innovative medicines to market for prevalent gynecologic infections that can have serious health consequences. Lupin Inc.AcquisitionUnited States
Cullinan Oncology$150 millionCullinan Oncology develops high value therapeutics geared towards dramatically improving the standard of care for those living with cancer.Cambridge venture capital firm MPM CapitaSeries A FinancingUnited States
Myovant Sciences$140 millionTo fund the ongoing Phase 3 development of its lead compound relugolix in uterine fibroids, endometriosis and prostate cancer.NovaQuest Capital Management ("NovaQuest") and 
Hercules Capital, Inc.
Flexible Financing United States
Universal Cells, Inc.$124 millionTo research, develop and commercialize a novel cell therapy for an undisclosed indicationAstellas Pharma Inc.Exclusive Worldwide RightsUnited States
OptiNose, Inc.$120 millionOptiNose, Inc. is a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists.Jefferies and Piper Jaffray, BMO
Capital Markets and RBC Capital Markets		IPO fundingUnited States
Vios Medical$102 million Vios Medical, Inc. is a U.S. based medical technology company focused on utilizing medical-grade IoT sensors and Virtual Patient Care Services to optimize the management of patientsMurata ManufacturingAcquisitionUnited States
GlaxoSmithKline$96 millionRaxibacumab is a fully human monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) for the treatment and prophylaxis of inhalational anthrax.Emergent BioSolutions IncProduct AcquisitionUnited Kingdom
Impact Biomedicines$90 millionTo advance the development, global supply chain build out, and future commercialization of fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor.Oberland Capital Structured FinancingUnited States
Roxwood Medical $80 millionRoxwood Medical is developer of innovative solutions to tackle some of the most complex procedures in interventional cardiology. BTG PlcAcquisitionUnited States
KSQ Therapeutics$76 millionTo advance the development of drugs empowered by the unique biological insights of its proprietary CRISPRomics™ drug discovery engine.Flagship Pioneering; Polaris Partners, 
ARCH Venture Partners, and Alexandria Equities
FinancingUnited States
Forty Seven Inc$75 million Expansion of ongoing clinical trials with CD47 antibody and initiation of new trials in combination with other immuno?oncology agents.Wellington Management Company LLP, 
Clarus, Lightspeed Venture Partners, 
Sutter Hill Ventures and 
GV (Google Ventures).
Series B FinancingUnited States
Arsanis $58 millionTo get its mid-stage pneumonia fighting antibody through Phase II and down the road to a potential approval.UndisclosedIPO fundingUnited States
InflaRx$55 million To foster its clinical stage complement anti-C5a development programsBain Capital Life Sciences LP, 
Cormorant Asset Management LLC and 
RA Capital Management LLC
Series D FinancingGermany
Y-mAbs Therapeutics, Inc.$50 millionTo focus on bringing lead compounds, burtomab and naxitamab, through the final steps of the regulatory pathway towards approvalHBM Healthcare InvestmentsEquity FinancingUnited States
Visterra, Inc$46.7 millionTo advance pipeline of precision antibody-based biological medicinesBill & Melinda Gates Foundation, 
MRL Ventures Fund, 
Vertex Venture Holdings Ltd Etc.
Series C FinancingUnited States
Eargo Inc$45 millionTo accelerate Eargo’s industry-leading product innovation, marketing and branding initiativesNan Fung Life Sciences & New Enterprise Associates, 
Charles and Helen Schwab, and Maveron
Series C FinancingUnited States
Gemini Therapeutics$42.5 millionTo develop precision therapeutics in ophthalmology and rare genetic diseasesAtlas Venture, Lightstone Ventures and OrbiMed Series A FinancingUnited States
Shockwave Medical$35 millionExpand commercialization and advance clinical development of the company’s Peripheral and Coronary Lithoplasty® Systems Fidelity Management & Research Company & 
T. Rowe Price Associates, Inc
FinancingUnited States
Kymera Therapeutics LLC$30 millionTo advance a transformational new therapeutic modality and discover breakthrough medicines for patients with previously untreatable diseases.Atlas Venture, Lilly Ventures and Amgen VenturesSeries A FinancingUnited States
PnuVax $29.4 millionTo further develop and clinically evaluate PnuVax’s innovative pneumococcal conjugate vaccine. Bill & Melinda Gates FoundationGrantCanada
TELA Bio$25 millionTo enhance commercial and clinical initiatives for distinct class of novel surgical implants for soft tissue repairPacira Pharmaceuticals Equity AgreementUnited States
Crystal Bioscience$25 millionCrystal Bioscience is a leader in avian genetics and the generation of fully-human therapeutic antibodiesLigand PharmaceuticalsAcquisitionUnited States
Impact Biomedicines$22.5 millionTo Bring Fedratinib to Myelofibrosis PatientsMedicxiSeries A FinancingUnited States
Profectus BioSciences$22.25 millionTo develop multi-component vaccine for Ebola, Marburg, and Lassa virusesNational Institute of Allergy and Infectious Diseases NIH FundingUnited States
DURECT Corporation$17.5 million Agreement relates to intellectual property for RBP-7000, Indivior's investigational once-monthly injectable Risperidone product for schizophreniaIndivior UK LimitedPatent Purchase AgreementUnited States
Avita Medical$16.9 millionUS ReCell commercialisation for burn injuries and to further evaluate new indicationsUndisclosedCapital RaisingUnited States
Ionis Pharmaceuticals$10 millionTo initiate Clinical Study of IONIS-MAPT Rx in Patients with Alzheimer's Disease.Biogen CollaborationUnited States
AstraZeneca$5 millionTo conduct a Phase II study for the treatment of alpha-1 antitrypsin deficiency (“AATD”), a congenital orphan condition.Mereo BioPharmaExclusive License AgreementUnited Kingdom
Carmel Biosciences$0.5 millionTo sell and market PREXXARTAN® (valsartan) oral solution in the United States and its territories.Medicure IncExclusive License to Sell & MarketUnited States
Arbutus UndisclosedTo develop novel RNA-based personalized neoantigen immunotherapies for cancer patientsGritstone Collaboration & License AgreementCanada
Dimension TherapeuticsUndisclosedTo create value by combining Dimension's innovative portfolio of assets and its advanced gene therapy platform with Ultragenyx's late-stage clinical, regulatory, and commercial expertise in the rare disease space.UltragenyxAcquisition United States
ABX GmbHUndisclosedEndocyte to focus resources on phase 3 registration trial of most advanced targeted radioligand therapy in development for prostate cancer, planned to initiate in first half 2018Endocyte, Inc.Exclusive Worldwide RightsGermany
Turnstone BiologicsUndisclosedTo license up to three of Turnstone's next-generation oncolytic viral immunotherapiesAbbVie Research, Option & License Agreement United States
Meiji Seika Pharma Co., Ltd.UndisclosedDevelopment and commercialization of SPR994, with potential to be the first broad-spectrum oral carbapenem for use in adults.Spero Therapeutics, Inc.Exclusive License AgreementJapan
Roivant Sciences UndisclosedDevelopment partnership for a deprioritized investigational drug in an undisclosed indication.AstraZeneca Partnership United States
Harpoon TherapeuticsUndisclosedTo incorporate Harpoon's tri-specific T-cell activating construct (TriTAC™) platform with AbbVie's research-stage immuno-oncology targets to develop novel cancer therapeuticsAbbVie CollaborationUnited States
CrestovoUndisclosedThe combination of a potential first-in-class product candidate for recurrent C. difficile infections with a novel technology platform for developing Rationally-Selected Microbiota™ products.Finch Therapeutics GroupMergerUnited States
AstraZenecaUndisclosed To manufacture and market Zomig®(zolmitriptan) , Market Migraine Medication In JapanUpsher-Smith Laboratories, LLC & 
 Sawai Pharmaceutical Co., Ltd
AgreementUnited Kingdom
Astellas Pharma IncUndisclosedTo discover antimalarial drugsMedicines for Malaria Venture (“MMV”)Screening Collaboration AgreementJapan
TB Alliance & Astellas Pharma Inc. UndisclosedTo discover anti- tuberculosis drugsGlobal Health Innovative Technology FundFinancingUnited States
Mitsubishi Tanabe Pharma Corporation & Daiichi Sankyo Company, LimitedUndisclosedConduct a program called “JOINUS” (Joint Open INnovation of drUg repoSitioning) to discover new therapeutic drugs using drug-repositioning compound libraries.Astellas Pharma IncCollaborationJapan
Medicines Patent Pool (MPP)UndisclosedTo expand access to bictegravir (BIC) upon regulatory approval in the United States.Gilead Sciences, Inc.License Agreement Switzerland
MedImmuneUndisclosedTo enter clinical trial collaboration in early lung cancerIncyte CorporationCollaboration United Kingdom
Applied BioMath, LLCUndisclosedFor quantitative systems pharmacology modeling in immuno-oncologySanofi USCollaboration United States
ASPiRA Labs, a Vermillion companyUndisclosedTo provide coverage for its in vitro diagnostic test, OVA1®.Joint Venture Hospital Laboratories, LLC ("JVHL"), 
QCA Health Plan of Arkansas, Inc. 
(d/b/a Qualchoice), 
Louisiana State Medicaid program, and 
Arizona State Medicaid Program
AgreementUnited States
TESARO, IncUndisclosedTo conduct a proof-of-concept clinical trial evaluating the combination of oregovomab with ZEJULA® (niraparib) in the recurrent ovarian cancer settingOncoQuest Inc.Collaborative Agreement United States
M2GenUndisclosedORIEN Avatar Program represents M2Gen's unique approach to accelerate the discovery and development of novel therapeutics for cancerBristol-Myers Squibb CollaborationUnited States
University of California San Francisco (UCSF)UndisclosedTo evaluate Apexigen's immune activating antibody APX005M in combination with multimodality treatment of resectable esophageal and gastro-esophageal junction cancers Apexigen, IncCollaboration United States
Biophore India Pharmaceuticals Pvt LtdUndisclosedTo bring a generic version of Valeant's Cuprimine and other penicillamine based generic products to the U.S. market.Amerigen Pharmaceuticals LimitedCollaboration India
PAREXEL International CorpUndisclosedForm cloud technology alliance aimed at accelerating the pace of drug developmentMicrosoft Collaboration United States
Cannatech LLCUndisclosedFor the acquisition of a 120-acre licensed industrial hemp farm in Amity, MEFuture Farm Technologies Inc. Definitive AgreementUnited States
Veritas Pharma IncUndisclosedPurchase of share Marapharm Ventures IncPurchase AgreementCanada
Genentech UndisclosedPhase 1b/2 study for the treatment of gastric cancer with BL-8040 in combination with atezolizumab (TECENTRIQ®)BioLineRxCollaborationUnited States
InsermUndisclosedTo study targeted nanotherapeutics for neurological diseaseGenisphere LLCCollaborative Research AgreementFrance
iBio, IncUndisclosedTo support potential large-scale production of the Aethlon Hemopurifier®Aethlon Medical, IncCollaboration United States
QIAGEN UndisclosedTo collaborate in bioinformatics for genetic diseasesCENTOGENE Collaboration Germany
Parata SystemsUndisclosedTo improve access to cutting edge technology American Associated PharmaciesGroup Purchasing AgreementUnited States
Catalent Pharma SolutionsUndisclosedFormulation development and clinical manufacturing agreement of THX-TS01, a first-in-class, proprietary investigational drug candidate for the treatment of the symptoms of Tourette syndrome.Therapix Biosciences LtdAgreement United States
Grid TherapeuticsUndisclosedTo develop a novel targeted immuno-oncology therapyCatalent Pharma SolutionsMulti-Year AgreementUnited States
MedivirUndisclosedThe exclusive worldwide rights to Medivir's research stage metallo-?-lactamase inhibitor (MBLI) programAMR Centre LtdExclusive Worldwide RightsSweden
Nostrum Laboratories IncUndisclosed5 ANDA's Three of the acquired assets are FDA approved and will be sold by Breckenridge under its label. Two of the assets are filed and pending with FDA with anticipated approval dates within the next 12 monthsBreckenridge Pharmaceutical, IncAcquisitionUnited States
Eisai IncUndisclosedTo commercialize HALAVEN® (eribulin mesylate), LENVIMA® (lenvatinib), FYCOMPA® (perampanel) and INOVELON® (rufinamide) throughout Latin AmericaGrupo BiotoscanaExclusive License AgreementJapan
Univec, IncUndisclosed To manufacture and distribute its medical cannabis transdermal patch for treatment and relief of approved medical conditionsAGRiMED IndustriesPartnership United States
SelectchemieUndisclosed License to register, market and sell Caspofungin Injection (systemic antifungal agent) in Saudi Arabia, the Gulf Countries, North Africa, and the rest of Middle EastTabuk Pharmaceutical Manufacturing Company License & Supply AgreementSwitzerland
SELLAS Life Sciences Group , LtdUndisclosedInitiation of a phase 1/2 combination clinical trial with Galinpepimut-S and KEYTRUDA® (Pembrolizumab) across various indications expected in 1H, 2018Merck & Co., Inc., Kenilworth, N.J., USASupply Agreement United States
OrexoUndisclosedPurchase Agreement of OX-MPI and to progress the candidate drug into proof-of-concept clinical trials. Gesynta Pharma ABPurchase Agreement Sweden
Celltrion HealthcareUndisclosedFor the distribution in Brazil of Herzuma®, the biosimilar TrastuzumabBiomm SADistribution Rights AgreementSouth Korea
Arcturus Therapeutics UndisclosedTo develop and commercialize nucleic acid-based drug products for the treatment of Hepatitis B, using Arcturus’ UNA Oligomer chemistry and LUNAR™ lipid-mediated delivery platformJanssen Pharmaceuticals, Inc 
(Johnson & Johnson)
Research Collaboration United States
Microbiology & Quality AssociatesUndisclosedAcquisition of microbiology & quality associates in the San-Francisco bay area.Analytical Lab GroupAcquisitionUnited States
Century MedicalUndisclosedAcquisition of spinal-related business of Century MedicalTeijin Nakashima MedicalAcquisition of Spinal Related BusinessJapan
Melvin Yahr International Parkinson's Disease FoundationUndisclosedTo support the next generation Parkinson's treatmentParkinson's Foundation, IncMergerUnited States
Core Clinical, Inc.UndisclosedMedical imaging core lab based in Bucks County, PA.Invicro AcquisitionUnited States
Eqova Life SciencesUndisclosedA Medically-focused CBD company.Grey Cloak Tech IncAcquisitionUnited States
Rhein Medical, IncUndisclosedProvider of premium ophthalmic surgical instruments and devices. Katena ProductsAcquisitionUnited States
mProve Health IncUndisclosedProvider of mobile technologies for life science companies. BraketAcquisitionUnited States
International Medical Management CorporationUndisclosedJapan’s largest supplier of unlicensed medicinesClinigenAcquisitionJapan
ResearchPoint GlobalUndisclosedA US-based contract research organization (CRO) with expertise spanning across all major therapeutic areas.WuXi AppTecAcquisitionUnited States
Surgical Process Institute UndisclosedGerman software company, a leading specialist for the standardization and digitalization of surgical workflows in the operating theatre.Johnson & Johnson Medical GmbH AcquisitionGermany
Cleveland HeartLab, IncUndisclosedTo identify and offer diagnostic services from Cleveland Clinic's innovations in inflammation and other areas of medicineQuest DiagnosticsAcquisitionUnited States
KNOW Bio, LLC UndisclosedTo treat viral malignancies with nitric oxideNovanExclusive Worldwide RightsUnited States
Evofem Biosciences, IncUndisclosedTo become a leading women’s health company that develops and commercializes novel products. Neothetics, IncMergerUnited States
Jazz Pharma Undisclosed LEUKOTAC® is an immunotherapy antibody with clinical benefits in steroidresistant acute Graft-versus-Host Disease.Elsalys BiotechWorldwide RightsIreland
SIMICON GMBHUndisclosedSIMICON manufactures both cleaning and biological indicatorsMesa Laboratories, IncAcquisition of All Outstanding SharesGermany
EpiontisUndisclosedNext-generation European specialty laboratory providing immune monitoring services through a novel, patent-protected epigenetic platform.Precision for MedicineAcquisitionGermany
Promet Therapeutics, LLCUndisclosedDevelops drug products to treat patients who have suboptimal and no treatment alternatives.Heatwurx, IncAcquisitionUnited States
Aviragen TherapeuticsUndisclosedDiscovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally.Vaxart, IncMergerUnited States
Aquila BioMedicalUndisclosedInnovative pre-clinical contract research organisation with expertise in immuno-oncology, immunology and multiplex histology.Concept Life Sciences AcquisitionUnited Kingdom
Shire PLCUndisclosedA clinical-stage mammalian manufacturing site in the United StatesLonza AcquisitionIreland
Humabs BioMed SA, Alnylam Pharmaceuticals, Inc., and Visterra, Inc.UndisclosedTo address serious infectious diseasesVir Biotechnology AgreementSwitzerland